Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2020-11-02 Share Issue/Capital Cha…
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Vicore stärker sin pipeline genom förvärv av nya AT2R agonister och beslutar om en apportemission om 142 054 aktier
Share Issue/Capital Change Classification · 99% confidence The document announces a corporate action: Vicore Pharma is acquiring patent rights for new AT2R agonists from HaLaCore Pharma AB. The key element of the announcement is the compensation method, which involves a cash payment and the issuance of 142,054 new shares to HaLaCore as consideration (an 'apportemission' or contribution in kind). This directly relates to changes in the company's capital structure and financing activities through the issuance of new shares as payment for an acquisition. This fits best under 'Capital/Financing Update' (CAP). It is not a standard earnings release (ER), interim report (IR), or annual report (10-K). While it involves share issuance, the primary context is the acquisition financed by shares, making CAP more specific than SHA (Share Issue/Capital Change) which usually covers splits or general rights issues, although CAP is the most appropriate fit for M&A-related financing.
2020-11-02 Swedish
Vicore Pharma offentliggör valberedningen inför årsstämman 2021
AGM Information Classification · 95% confidence The document is titled "Vicore Pharma offentliggör valberedningen inför årsstämman 2021" (Vicore Pharma announces the Nomination Committee for the 2021 Annual General Meeting). It details the composition of the Nomination Committee, its tasks (preparing proposals for the AGM), and the deadline for shareholder input regarding the AGM scheduled for May 11, 2021. This content directly relates to the preparation and governance surrounding the Annual General Meeting (AGM). While it is an announcement, the subject matter is specifically about the AGM's preparatory body (the Nomination Committee), which falls under the broader scope of AGM-related materials, rather than a general regulatory filing (RNS) or a proxy solicitation (PSI) which typically solicits votes. Given the specific focus on the Nomination Committee for the AGM, AGM-R is the most appropriate classification, as it covers AGM presentations and materials, and this announcement is a key preparatory step for that meeting.
2020-10-06 Swedish
Vicore Pharma announces the Nomination Committee for the 2021 Annual General Meeting
Board/Management Information Classification · 99% confidence The document explicitly announces the formation and composition of the Nomination Committee for the upcoming 2021 Annual General Meeting (AGM). It details the members appointed by major shareholders and outlines the committee's tasks related to the AGM (proposing board members, fees, etc.). This content is directly related to the governance and preparation for the Annual General Meeting. While it mentions the AGM date, the core subject is the committee formation, which falls under the scope of AGM-related materials, specifically the preparation for the meeting itself. Therefore, AGM-R (AGM Information) is the most appropriate classification.
2020-10-06 English
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for Vicore Pharma Holding AB by HBM Healthcare Investments (Cayman) Ltd. It explicitly shows the 'Before the transaction' and 'After the transaction' share quantities and voting rights percentages. The key phrase is 'Reason for major shareholding notification'. This structure perfectly matches the definition of a Major Shareholding Notification, which is classified as 'MRQ'. The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2020-08-31 English
Ökning av antalet aktier och röster i Vicore Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a short announcement from Vicore Pharma dated August 31, 2020, detailing an increase in the number of outstanding shares and registered share capital following a directed new share issue (nyemission) of 10,000,000 shares. This directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV).
2020-08-31 Swedish
Increase of number of shares and votes in Vicore Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces an 'Increase of number of shares and votes' following a directed share issue resolved by the board based on authorization from the AGM. It details the number of new shares issued (10,000,000), the subscription price (SEK 18.50), the proceeds (SEK 185 million), and the resulting total number of outstanding shares (60,418,239) and registered share capital. This content directly relates to changes in the company's capital structure due to new share issuance, which aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). It is not a general financing update (CAP) as it is a specific post-issuance notification, nor is it a transaction in own shares (POS) as it describes the issuance of *new* shares.
2020-08-31 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.